The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

Jr., Pedro N. Aguiar; Santoro, Ilka Lopes; Tadokoro, Hakaru; Lopes, Gilberto de Lima; Filardi, Bruno Andraus; Oliveira, Pedro; Mountzios, Giannis; de Mello, Ramon Andrade

http://hdl.handle.net/10400.1/9557

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
H.9557.pdf		1.92 MB	Adobe PDF	Download

Send Feedback

Authors

Jr., Pedro N. Aguiar

Santoro, Ilka Lopes

Tadokoro, Hakaru

Lopes, Gilberto de Lima

Filardi, Bruno Andraus

Oliveira, Pedro

Mountzios, Giannis

de Mello, Ramon Andrade

Abstract(s)

Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.